Organon & Co- 详细介绍、公司背景、业务范围、财务数据以及市场表现

关于 Organon & Co 公司

Organon & Co. is a global healthcare company. The Company is engaged in developing and delivering health solutions through a portfolio of prescription therapies and medical devices within women's health, biosimilars and a franchise of established medicines across a range of therapeutic areas. It has a portfolio of approximately 70 medicines and products across a range of therapeutic areas. It has a portfolio of contraception and fertility brands, including Nexplanon, NuvaRing, and Follistim AQ. Its Biosimilars portfolio spans across immunology and oncology treatments. It also has a portfolio of established brands, including brands in cardiovascular, dermatology and non-opioid pain management. It sells these products through various channels, including drug wholesalers and retailers, hospitals, government agencies and managed health care providers, such as pharmacy benefit managers and other institutions.

Organon & Co简介



公司代码OGN

公司名称Organon & Co

上市日期May 14, 2021

CEOMorrissey (Joseph T)

员工数量10000

证券类型Ordinary Share

年结日May 14

公司地址30 Hudson Street

城市JERSEY CITY

上市交易所NASDAQ OMX NASDAQ Basic NYSE

国家United States of America

邮编07302

电话15514306000

网址https://www.organon.com/

公司代码OGN

上市日期May 14, 2021

CEOMorrissey (Joseph T)

Organon & Co公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Matthew M. (Matt) Walsh

Chief Financial Officer, Executive Vice President

212.09K

+15.09%

Ms. Rachel A. Stahler

Executive Vice President, Chief Digital and Growth Officer

108.69K

+16.37%

Mr. Aaron Falcione

Chief Human Resources Officer, Executive Vice President

96.76K

+17.90%

Mr. Kirke Weaver

Executive Vice President, General Counsel, Corporate Secretary

91.17K

+20.61%

Mr. Vittorio Nisita

Executive Vice President, Head of Enterprise Services & Solutions

66.76K

+18.48%

Ms. Rochelle B. (Shelly) Lazarus

Independent Director

633.00

--

Ms. Shalini Sharp

Independent Director

2.00

--

Mr. Robert A. (Bob) Essner

Lead Independent Director

--

Ms. Cynthia M. Patton

Independent Director

--

Ms. Grace M. Puma Whiteford

Independent Director

--

名称

名称/职务

职务

持股

持股变动

Mr. Matthew M. (Matt) Walsh

Chief Financial Officer, Executive Vice President

212.09K

+15.09%

Ms. Rachel A. Stahler

Executive Vice President, Chief Digital and Growth Officer

108.69K

+16.37%

Mr. Aaron Falcione

Chief Human Resources Officer, Executive Vice President

96.76K

+17.90%

Mr. Kirke Weaver

Executive Vice President, General Counsel, Corporate Secretary

91.17K

+20.61%

Mr. Vittorio Nisita

Executive Vice President, Head of Enterprise Services & Solutions

66.76K

+18.48%

Ms. Rochelle B. (Shelly) Lazarus

Independent Director

633.00

--

收入明细

单位: USD更新时间: 4月6日周一

FY2025

FY2025Q4

FY2025Q3

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

业务USD

名称

营收

占比

Women’s Health

1.75B

28.19%

Cardiovascular

1.14B

18.26%

Non-Opioid Pain, Bone and Dermatology

987.00M

15.88%

Respiratory

842.00M

13.55%

Other

809.00M

13.01%

Biosimilars

691.00M

11.12%

地区USD

名称

营收

占比

Europe and Canada

1.62B

26.03%

United States

1.60B

25.80%

Latin America, Middle East, Russia and Africa

1.07B

17.25%

Asia Pacific and Japan

1.00B

16.09%

China

829.00M

13.34%

Other

93.00M

1.50%

业务

地区

业务USD

名称

营收

占比

Women’s Health

1.75B

28.19%

Cardiovascular

1.14B

18.26%

Non-Opioid Pain, Bone and Dermatology

987.00M

15.88%

Respiratory

842.00M

13.55%

Other

809.00M

13.01%

Biosimilars

691.00M

11.12%

股东统计

更新时间: 5月10日周日

持股股东

股东类型

持股股东

占比

BlackRock Institutional Trust Company, N.A.

10.79%

Vanguard Portfolio Management, LLC

8.32%

Vanguard Capital Management, LLC

4.47%

State Street Investment Management (US)

3.65%

AQR Capital Management, LLC

3.26%

其他

69.50%

持股股东

占比

BlackRock Institutional Trust Company, N.A.

10.79%

Vanguard Portfolio Management, LLC

8.32%

Vanguard Capital Management, LLC

4.47%

State Street Investment Management (US)

3.65%

AQR Capital Management, LLC

3.26%

其他

69.50%

股东类型

持股股东

占比

Investment Advisor

43.53%

Investment Advisor/Hedge Fund

19.78%

Hedge Fund

6.71%

Research Firm

3.26%

Pension Fund

2.50%

Bank and Trust

0.95%

Individual Investor

0.48%

Sovereign Wealth Fund

0.10%

Venture Capital

0.10%

其他

22.59%

机构持股



更新时间: 4月1日周三

报告期

机构数

持股数

持股占比

持股变动

2026Q1

1398

239.27M

91.12%

-3.99M

2025Q4

1391

200.94M

77.29%

-50.68M

2025Q3

1485

219.88M

84.58%

-37.41M

2025Q2

1527

205.34M

78.98%

-50.49M

2025Q1

1611

213.21M

82.04%

-52.34M

2024Q4

1647

218.39M

84.67%

-40.43M

2024Q3

1625

211.80M

82.26%

-47.57M

2024Q2

1676

208.67M

81.14%

-51.47M

2024Q1

1700

205.29M

80.30%

-45.21M

2023Q4

1767

202.90M

79.38%

-24.07M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

BlackRock Institutional Trust Company, N.A.

28.33M

10.88%

+577.06K

+2.08%

Dec 31, 2025

State Street Investment Management (US)

9.60M

3.69%

+262.19K

+2.81%

Dec 31, 2025

AQR Capital Management, LLC

8.57M

3.29%

+4.39M

+105.24%

Dec 31, 2025

LSV Asset Management

7.47M

2.87%

-362.11K

-4.62%

Dec 31, 2025

MFS Investment Management

6.88M

2.64%

-2.55M

-27.03%

Dec 31, 2025

Kahn Brothers Advisors LLC

3.63M

1.39%

+12.61K

+0.35%

Dec 31, 2025

Geode Capital Management, L.L.C.

4.60M

1.77%

-215.10K

-4.47%

Dec 31, 2025

Private Management Group, Inc.

4.35M

1.67%

+1.20M

+38.35%

Dec 31, 2025

持股ETF



更新时间: 12月2日周二

机构名称

占比

State Street SPDR S&P Pharmaceuticals ETF

1.72%

Alger Russell Innovation ETF

1.39%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

1.22%

First Trust Health Care Alphadex Fund

1.1%

Invesco S&P SmallCap Health Care ETF

1.07%

Brandes US Small-Mid Cap Value ETF

1.05%

iShares U.S. Pharmaceuticals ETF

0.65%

Lattice Hartford Multifactor Small Cap ETF

0.5%

WisdomTree U.S. SmallCap Dividend Fund

0.5%

Royce Quant Small-Cap Quality Value ETF

0.45%

State Street SPDR S&P Pharmaceuticals ETF

占比1.72%

Alger Russell Innovation ETF

占比1.39%

Direxion Daily Pharmaceutical & Medical Bl 3X ETF

占比1.22%

First Trust Health Care Alphadex Fund

占比1.1%

Invesco S&P SmallCap Health Care ETF

占比1.07%

Brandes US Small-Mid Cap Value ETF

占比1.05%

iShares U.S. Pharmaceuticals ETF

占比0.65%

Lattice Hartford Multifactor Small Cap ETF

占比0.5%

WisdomTree U.S. SmallCap Dividend Fund

占比0.5%

Royce Quant Small-Cap Quality Value ETF

占比0.45%

分红派息



近5年累计派现 1.03B 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

Apr 30, 2026

OGN.NB Interim Cash Dividend of gross USD 0.02 paid on Jun 11, 2026 going ex on May 11, 2026

May 11, 2026

Jun 11, 2026

May 11, 2026

Feb 12, 2026

OGN.NB Interim Cash Dividend of gross USD 0.02 paid on Mar 12, 2026 going ex on Feb 23, 2026

Feb 23, 2026

Mar 12, 2026

Feb 23, 2026

Nov 10, 2025

OGN.NB Final Cash Dividend of gross USD 0.02 paid on Dec 11, 2025 going ex on Nov 20, 2025

Nov 20, 2025

Dec 11, 2025

Nov 20, 2025

Aug 05, 2025

OGN.NB Interim Cash Dividend of gross USD 0.02 paid on Sep 11, 2025 going ex on Aug 15, 2025

Aug 15, 2025

Sep 11, 2025

Aug 15, 2025

May 01, 2025

OGN.NB Interim Cash Dividend of gross USD 0.02 paid on Jun 12, 2025 going ex on May 12, 2025

May 12, 2025

Jun 12, 2025

May 12, 2025

Feb 13, 2025

OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Mar 13, 2025 going ex on Feb 24, 2025

Feb 24, 2025

Mar 13, 2025

Feb 24, 2025

Oct 31, 2024

OGN.NB Final Cash Dividend of gross USD 0.28 paid on Dec 12, 2024 going ex on Nov 12, 2024

Nov 12, 2024

Dec 12, 2024

Nov 12, 2024

Aug 06, 2024

OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Sep 12, 2024 going ex on Aug 16, 2024

Aug 16, 2024

Sep 12, 2024

Aug 16, 2024

May 02, 2024

OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Jun 13, 2024 going ex on May 10, 2024

May 13, 2024

Jun 13, 2024

May 10, 2024

Feb 15, 2024

OGN.NB Interim Cash Dividend of gross USD 0.28 paid on Mar 14, 2024 going ex on Feb 23, 2024

Feb 26, 2024

Mar 14, 2024

Feb 23, 2024

拆合股



公告日期

除权除息日

类型

比率

暂无数据

公告日期

除权除息日

类型

比率

暂无数据